Tim Anderson, an analyst from Bank of America Securities, reiterated the Buy rating on Apogee Therapeutics. The associated price target remains the same with $78.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Buy rating due to a combination of factors influencing Apogee Therapeutics’ potential in the market. The recent release of 16-week topline data from the Phase 2 APEX study of APG777 in atopic dermatitis demonstrates promising efficacy and safety results. The standout feature of APG777 is its extended dosing frequency, which could offer a significant advantage over existing treatments by reducing the frequency of injections needed by patients.
Looking ahead, while the rest of 2025 may see limited developments, key data releases are expected in 2026, including further maintenance data and trial results for APG279. These developments could enhance Apogee’s position in the under-penetrated atopic dermatitis market. Despite potential challenges in securing payer coverage, the differentiation offered by APG777 and the potential of other programs like APG279 support the Buy rating, with a price objective set at $78, reflecting confidence in the company’s future growth prospects.
According to TipRanks, Anderson is a 4-star analyst with an average return of 10.8% and a 65.22% success rate. Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Regeneron.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $95.00 price target.